Ipilimumab activity in advanced uveal melanoma

Area of Science:

• Oncology
• Immunotherapy
• Melanoma Research

Background:

• Uveal melanoma (UM) is a rare primary eye cancer with a poor prognosis for metastatic disease.
• Limited treatment options exist for advanced UM, with no established survival benefit from current therapies.
• Ipilimumab has demonstrated survival benefits in cutaneous melanoma but its role in UM is less defined.

Purpose of the Study:

• To evaluate the efficacy and safety of ipilimumab in patients with advanced uveal melanoma.
• To assess treatment response patterns and tumor kinetics in UM patients treated with ipilimumab.

Main Methods:

• Retrospective case series of five patients with advanced UM treated with ipilimumab at a UK academic cancer center.
• Assessment of tumor response, stable disease, and progression based on clinical data.
• Analysis of tumor kinetics and response patterns.

Main Results:

• Two out of five patients achieved durable stable disease.
• One patient maintained disease control for 11 months with a 10% tumor volume reduction.
• The second patient with stable disease progressed after 15 months; three patients developed progressive disease.
• Observed tumor kinetics and response patterns were similar to those seen in ipilimumab-treated cutaneous melanoma.

Conclusions:

• Ipilimumab may represent a reasonable treatment option for patients with advanced uveal melanoma.
• Further investigation, including randomized trials, is warranted to confirm ipilimumab's role in UM management.
• The findings suggest potential efficacy despite the lack of extensive prior evidence in UM.